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Background: Although studies have examined the relationship between metabolic syndrome 
(MetS) and COPD, the incidence of MetS in individuals with COPD has not specifically been 
investigated. This study aimed to evaluate the incidence of MetS in subjects with airway obstruc-
tion using data from a community-based cohort. 
Patients and methods: Data representing 4 years of follow-up from the Ansung–Ansan cohort 
were analyzed; a total of 6,184 adults, who were $40 years of age and underwent spirometry, 
were enrolled in this study. Airway obstruction was defined as forced expiratory volume in 
1 s/forced vital capacity ratio ,70%, and MetS was determined according to the National 
Cholesterol Education Program Adult Treatment Panel III guidelines. 
Results: A total of 419 patients were newly diagnosed with MetS, based on the National 
Cholesterol Education Program Adult Treatment Panel III guidelines, during follow-up. MetS 
was more frequent in COPD subjects, relative to non-COPD subjects, in both sexes (14.7% vs 
11.0% [men] and 14.7% vs 11.8% [women]). In men subjects, the risk for MetS was higher in 
subjects with airflow obstruction than in subjects without obstruction, after adjusting for age, 
body mass index, and smoking status.
Conclusion: The incidence of MetS was higher in men with airflow obstruction than in healthy 
subjects. 
Keywords: COPD, metabolic syndrome, incidence
Introduction
COPD is characterized by persistent air-flow limitation that is typically progressive1 
and is a major cause of morbidity and mortality worldwide.2 Metabolic syndrome 
(MetS) has been associated with several diseases, including cardiovascular disease, 
as well as with increased exacerbation of underlying disease and mortality risk.3–5 
As COPD and MetS both constitute major public health problems, more precise 
and informative epidemiological data are needed regarding the relationship between 
COPD and MetS.
Previous studies have evaluated the prevalence of MetS in COPD patients and normal 
subjects.6,7 In addition, a Korean study reported a relatively higher prevalence of MetS 
in patients with COPD, compared with healthy subjects.8,9 However, there have been no 
community-based cohort studies investigating the incidence of MetS in COPD patients. 
Many of the previous studies regarding MetS in COPD were cross-sectional and 
primarily focused on the prevalence, rather than the incidence, of MetS in patients with 
COPD. Thus, the present study aimed to evaluate the incidence and characteristics of 
MetS in COPD patients using data from a large community-based cohort.
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Patients and methods
study population
Prospectively collected data from the Ansung–Ansan cohort 
were used for this analysis. The Ansung–Ansan cohort is a 
community-based sample that was evaluated in the Korean 
Genome and Epidemiology study (KoGES). The KoGES 
cohort included subjects from both the Ansan (urban) and 
Anseong (rural) areas of Korea for prospective investigation. 
Detailed information regarding the study design and protocols 
has been previously published.10 The baseline survey of the 
Ansung–Ansan cohort was conducted between May 2001 
and February 2003; the present study included 8,843 eligible 
adults who were 40–69 years of age. Follow-up examinations 
were performed biennially. Of these subjects, 6,676 were 
reevaluated after 4 years, corresponding with a follow-up 
rate of 75.4% in the secondary survey (2005–2006). Subjects 
who did not undergo pulmonary function testing at baseline 
and follow-up after 4 years (n = 492) were excluded. Of the 
remaining 6,184 subjects, a further 2,298 were excluded 
because they exhibited MetS in the baseline survey. Although 
subjects were diagnosed with COPD at the time of the baseline 
survey, those exhibiting normal pulmonary function results in 
the secondary survey were excluded (n = 118), as were par-
ticipants with normal lung function who exhibited COPD in 
the second investigation (n = 163). Ultimately, a total of 3,604 
subjects were included in the final analysis (Figure 1).
Definition of MetS and airflow obstruction 
MetS was defined clinically based on the presence of $3 of 
the following modified Adult Treatment Panel III revised 
guidelines:11 central obesity (with waist circumference cutoff 
points of .90 cm for men and .80 cm for women); an 
elevated triglyceride level ($1.7 mmol/L or undergoing drug 
treatment for elevated triglyceride levels); a reduced high-
density lipoprotein cholesterol (HDL-C) level (,1.0 mmol/L 
[men], ,1.3 mmol/L [women], or drug treatment for 
reduced HDL-C); elevated blood pressure ($130 mmHg 
systolic, $85 mmHg diastolic, or antihypertensive drug 
treatment in patients with a history of hypertension); and an 
elevated fasting plasma glucose concentration ($5.6 mmol/L 
or drug treatment for diabetes).
Lung function tests were performed by a skilled tech-
nician using a portable spirometer (Vmax-2130, Sensor 
Medics, Yorba Linda, CA, USA) in accordance with stan-
dardized protocols from the American Thoracic Society.12 
All participants underwent pulmonary function testing 
during each visit (at baseline as well as the first and second 
follow-up visits). Calibration and quality control of spiro-
metric examinations were performed regularly, based on 
American Thoracic Society guidelines.12 Airflow obstruc-
tion was defined as a prebronchodilator forced expiratory 
volume in 1 second (FEV
1
)/forced vital capacity (FVC) 
ratio of ,0.7. 
Figure 1 study population and design.
Note: *Airflow obstruction: forced expiratory volume in 1 second/forced vital capacity ratio , 0.7.
Abbreviation: Mets, metabolic syndrome.
8,843 participants were assessed
for eligibility
6,676 participants were assessed
for eligibility
6,184 participants included for
analysis
3,604 participants were included
for MetS incidence analysis
163 normal participants converted into
airflow obstruction* in second investigation
118 participants with airflow obstruction*
converted into normal in second investigation
2,298 MetS participants in
first investigation were excluded
2,167 declined to
participate after 4 years
492 participants who did
not undergo spirometry
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statistical analysis
All values are expressed as mean ± standard deviation. 
Continuous and categorical variables were compared using 
Student’s t-test and the chi-squared/Fisher’s exact test, 
respectively. Logistic regression analyses were performed 
to estimate odds ratios (ORs) with 95% confidence intervals 
(CIs) for MetS development, after adjusting for other con-
founding variables; P , 0.05 was considered to be statisti-
cally significant. Statistical analyses were performed using 
SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
ethics approval
The Korean Centers for Disease Control and Prevention 
obtained written informed consent from all participants, 
and the Institutional Review Board of Severance Hospital 
(Seoul, South Korea) approved the study protocol (4-2016-
0458). The data accessed from the KoGES cohort study is 
anonymous.
Results
Baseline patient characteristics 
Table 1 describes the baseline characteristics of all patients 
who were included in the analysis. In total, 3,604 subjects 
(51.1% men, 45.9% women) were included in our analysis. 
The mean age of the patients was 50.5 ± 8.4 years. There was 
an age difference between men and women (50.8 ± 8.5 vs 
50.0 ± 8.3, P = 0.004). Among all included subjects, 23.1% 
and 4.3% exhibited hypertension and diabetes mellitus, 
respectively. The proportion of current smokers was 44.1% 
of male subjects and 2.5% of female subjects (P , 0.001).
The average body mass index (BMI) was 23.9 kg/m2, with 
female subjects exhibiting a relatively lower mean BMI than 
male subjects (24.0 kg/m2 vs 23.8 kg/m2, P = 0.015). There 
were no differences in lung function or physical activity 
between male and female subjects. At baseline, 252 of 3,604 
(7.0%) subjects exhibited airflow obstruction. The propor-
tion of male subjects with COPD was significantly higher 
than the proportion of female subjects with COPD (11.8% 
vs 1.9%, P , 0.001). The median follow-up duration was 
4 years (interquartile range: 3.0–4.0 years).
Incidence of Mets
During the follow-up period, 11.6% (n = 419) of patients 
developed MetS based on the National Cholesterol Education 
Program Adult Treatment Panel III guidelines.11 The inci-
dence of MetS was higher in patients with COPD, relative to 
those without COPD, for both sexes (11.0% vs 14.7% [men] 
and 11.8% vs 14.7% [women]) (Figure 2). Table 2 shows 
the result of a multivariate logistic regression analysis of risk 
factors for MetS. After adjusting for confounding variables, 
Table 1 Baseline characteristics of men and women subjects included in the study
Characteristics Men
(n = 1,840)
Women
(n = 1,764)
Total
(n = 3,604)
P-value
age (years), mean 50.8 ± 8.5 50.0 ± 8.3 50.5 ± 8.4 0.004
BMI (kg/m2), mean 24.0 ± 2.7 23.8 ± 2.7 23.9 ± 2.7 0.015
COPD, n (%) 218 (11.8) 34 (1.9) 252 (7.0) ,0.001
hypertension, n (%) 505 (27.4) 329 (18.7) 834 (23.1) ,0.001
Diabetes mellitus, n (%) 110 (6.0) 44 (2.5) 154 (4.3) ,0.001
Income quartile, n (%) ,0.001
First 436 (23.9) 543 (31.6) 979 (27.6)
second 561 (30.7) 545 (31.7) 1,106 (31.2)
Third 640 (35.0) 510 (29.6) 1,150 (32.4)
Fourth 189 (10.4) 123 (7.1) 312 (8.8)
smoking status, n (%) ,0.001
never smoker 420 (22.9) 1,673 (96.3) 2,093 (58.6)
ex-smoker 605 (33.0) 21 (1.2) 626 (17.5)
Current smoker 809 (44.1) 43 (2.5) 852 (23.9)
smoking, pack-year 23.1 ± 16.7 23.6 ± 16.8 9.4 ± 9.5 ,0.001
FeV1, % predicted, mean 108.3 ± 15.8 117.8 ± 16.8 112.9 ± 17.0 ,0.001
FVC, % predicted, mean 103.1 ± 13.5 108.1 ± 14.6 105.6 ± 14.3 ,0.001
Physical activity,a n (%) 0.002
None/mild 835 (46.4) 823 (47.9) 1,658 (47.1)
Moderate 613 (34.1) 642 (37.3) 1,255 (35.7)
Vigorous 352 (19.6) 254 (14.8) 606 (17.2)
Notes: Data are presented as mean ± standard deviation or n (%). aDefined as none/mild: 0–29 minutes/day; moderate 30–60 minutes/day; vigorous $60 minutes/day. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. 
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such as age, BMI, and smoking, male patients with airflow 
obstruction were 1.76-fold (95% CI 1.04–2.96, P = 0.028) 
more likely to develop MetS, relative to normal subjects. 
Thus, the risk for MetS in subjects with airway obstruction 
was higher in the subgroup of male subjects, following adjust-
ment for age, BMI, smoking, and physical activity.
Discussion
This is the first study to confirm the incidence of Mets in 
COPD patients via data from a large community-based 
cohort. The incidence of MetS was higher in the airflow 
obstruction group, even after adjustment for other confound-
ing factors, including age, BMI, smoking, and physical 
activity, in male subjects. This finding is consistent with 
previous studies that have reported an increased prevalence 
of MetS in patients with COPD. However, clinical implica-
tion of the present study is that it was the first to evaluate 
and compare the incidence of MetS between patients with 
and without airflow obstruction.
In the present study, incidence of MetS was higher in 
patients with impaired lung function. However, a strength of 
our study was that we defined the airflow obstruction group 
according to airflow limitation, rather than FEV
1
 quartile 
or changes in FVC. Previously, Kim et al investigated the 
incidence of MetS in patients with impaired lung function.13 
In that study, changes in vital capacity over a 6-year period 
were associated with development of MetS, which itself was 
associated with obesity and abdominal obesity. However, 
the patients included in that study did not exhibit COPD, 
nor were they enrolled from a community-based sample. 
Another group attempted to characterize the incidence of 
MetS using 2-year follow-up data from Health Screening 
Centers in Taiwan.14 In contrast to the present study, the 
follow-up duration in the Taiwan-based study was short 
and the target group was divided according to FEV
1
, rather 
than airflow limitation; furthermore, the target group was 
not a community-based cohort. There is significant disparity 
between the present study and previous studies regarding the 
accuracy of the definition of airflow obstruction. 
Some studies have reported an association between 
COPD and MetS. Recent reviews revealed that the mean 
prevalence of MetS in patients with COPD was 32% (range 
23%–58%), compared with 30% (range 17%–54%) in 
controls. Moreover, the average reported prevalence of MetS 
varies among different regions, with a lower prevalence in 
studies from Asia (28%), relative to European (41%) and 
American studies (53%).6 Furthermore, the difference in 
MetS prevalence between COPD patients and controls was 
small, which may be related to the inclusion of subjects 
without COPD, but with other comorbidities, in the control 
group. In this study, we confirmed the prevalence of MetS 
in both populations (34.8%), relative to the control group 
(28.4%). The rates revealed in the present study are consistent 
with other recent reports. Additionally, the 4-year incidence 
of MetS was higher in the airflow obstruction group, rela-
tive to the control group. Several groups have investigated 
the incidence of MetS using different diagnostic methods, 
20%
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11.8%
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P = 0.106 P = 0.602
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COPD–
(N = 1,730)
COPD+
(N = 34)
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Figure 2 Incidence of metabolic syndrome in patients with COPD at 4 years of 
follow-up.
Notes: Data are expressed as number and percentage. Metabolic syndrome devel-
oped in 11.6% of the total subjects (419/3,604). Incidence of metabolic syndrome 
in patients with COPD was compared to incidence in patients without COPD, in 
both sexes.
Table 2 association between metabolic syndrome and lung function impairment at 4 years of follow-up
Characteristic Men
OR (95% CI)
P-value Women
OR (95% CI)
P-value Total
OR (95% CI)
P-value
age 1.02 (1.00–1.05) 0.040 1.08 (1.05–1.10) ,0.001 1.05 (1.03–1.07) ,0.001
BMI 1.26 (1.18–1.34) ,0.001 1.31 (1.23–1.40) ,0.001 1.29 (1.23–1.35) ,0.001
smoking 1.73 (1.06–2.81) 0.035 1.30 (0.29–5.88) 0.730 1.33 (0.97–1.83) 0.082
COPD 1.76 (1.04–2.96) 0.028 0.35 (0.07–1.92) 0.229 1.23 (0.76–1.97) 0.401
Physical activity 0.89 (0.19–4.30) 0.875 1.08 (0.28–4.19) 0.914 1.08 (0.40–2.92) 0.877
Note: Data are presented as odds ratio (OR) (95% confidence interval [CI]), adjusted for age, body mass index (BMI), COPD, physical activity, and metabolic syndrome 
incidence in multivariable logistic regression analysis.
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including spirometry and health care databases.15–17 A study 
by Breyer et al revealed that the prevalence of MetS was 
higher in patients with COPD.18 Similarly, in a study 
involving Asian subjects, the risk for MetS was higher in 
individuals with airflow obstruction, relative to individuals 
without obstruction, even after adjustment for potential 
confounders.19 Additionally, a Korean study that used data 
from a nationwide survey reported that the risk for MetS 
was higher in sarcopenic males with COPD;8 notably, the 
prevalence of MetS was also higher.9 Previous studies, 
however, have sought to evaluate the relationship between 
COPD and MetS primarily through measurement of the 
prevalence of MetS. The findings from our study are unique 
in that we are the first to report the incidence of MetS in 
patients with COPD using data from a large community-
based cohort. In contrast to other studies, the present study 
involved repeated measurements of pulmonary function and 
participants were more accurately categorized according to 
airflow obstruction, which differs from the methods used in 
previous investigations.
Many studies have investigated the relationship between 
COPD and the presence of comorbidities. In patients with 
COPD and MetS, cardiovascular comorbidities are more 
prevalent and are associated with an increased mortality, 
largely related to the aggravation of underlying disease.20,21 
A possible explanation for higher incidence of MetS among 
COPD patients may be that COPD patients with MetS are 
physically less active and exhibit increased levels of systemic 
inflammation relative to healthy patients.22,23 However in this 
study, these particular differences were not clearly observed, 
perhaps because the number of patients with MetS was 
insufficient; moreover, patients with severe and very severe 
airflow obstruction were not included in the analysis. 
Although pathophysiological consequences of MetS 
remain controversial, insulin resistance may play a crucial 
role.24 Findings of the present study regarding airflow 
obstruction and occurrence of insulin resistance, which 
was defined as increased fasting plasma glucose levels, are 
generally consistent with previous studies.14 For example, 
Lawlor et al25 observed an inverse association between 
insulin resistance and lung function, following adjustment 
for important confounding factors. In addition, Lazarus 
et al26 reported that decreased lung function at baseline 
predicted insulin resistance over 20 years of follow-up, 
independent of age, BMI, waist-to-hip ratio, or cigarette 
smoking status. Additional studies have demonstrated that 
patients with impaired lung function carry an increased 
risk for developing insulin resistance and type 2 diabetes 
mellitus.27–29 Consistent with these findings, we found that 
the percentage change in glucose level was higher in patients 
with COPD, suggesting that insulin resistance may be an 
independent risk factor for the incidence of MetS among 
COPD patients (Figure 3). 
According to the International Diabetes Federation, the 
prevalence of MetS is largely affected by abdominal obesity. 
Indeed, patients with obstructive lung disease exhibit more 
visceral fat mass, relative to healthy subjects.30 In the present 
study, these findings are indirectly confirmed by the observa-
tion that the incidence of MetS was higher in individuals with 
a higher BMI (25.5 kg/m2 vs 23.7 kg/m2). It remains unclear 
why abdominal obesity is more prevalent in COPD patients 
than in healthy subjects; however, various factors, including 
poor nutrition and inactive lifestyle, may play an important 
role.30 Future longitudinal studies with larger sample sizes 
are required to further investigate the causal relationship 
between COPD and MetS. 
Our study has several strengths. To our knowledge, 
this was the first study to evaluate the incidence of MetS in 
patients with airflow obstruction. Second, we evaluated the 
risk for MetS using a relatively large community-based popu-
lation with a relatively long duration of follow-up. Third, we 
accurately classified patients as COPD or non-COPD through 
repeated pulmonary function tests; moreover, we obtained 
MetS data via laboratory tests and accurate medical history, 
rather than through patient interviews. 
Our study also included multiple limitations. First, we 
could not analyze other important comorbidities, such as 
cardiovascular disease and malignancies, because of the 
absence of objective data regarding both factors. Second, 
most patients with airway obstruction were classified as 
exhibiting mild or moderate disease; the exclusion of patients 
with severe disease, therefore, may have influenced our 
results. Third, the incidence of MetS was higher in only male 
subjects, which might be influenced by smoking status and 
low event number in female subjects (n = 5). Further, large 
prospective studies are needed to more clearly elucidate the 
relationship between airflow obstruction and the incidence 
of MetS in the general population.
Conclusion
The incidence of MetS was higher in COPD patients, relative 
to controls, and was most influenced by fasting blood glucose 
level and high blood pressure. The incidence of MetS was 
higher in older, male COPD subjects, who exhibited higher 
BMI and more severe smoking status. Future longitudinal and 
interventional studies are needed to elucidate the relationship 
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between airflow obstruction and the incidence of MetS in 
the general population.
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